Submissions for variant NM_000463.2(UGT1A1):c.-53_-52insTA

dbSNP: rs1559406508

Total submissions: 3

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
Eurofins Ntd Llc (ga)	RCV000730016	SCV000857723	other	not provided	2017-10-18	criteria provided, single submitter	clinical testing
Rady Children's Institute for Genomic Medicine, Rady Children's Hospital San Diego	RCV004545798	SCV004014867	pathogenic	UGT1A1-related disorder		criteria provided, single submitter	clinical testing	This variant is also referred to as (TA)7 or UGT1A1*28 in the literature, and is located in the TATA box of the UGT1A1 promoter region (PMID:7565971). Variants that change the TATA repeat length from its usual length of 6 TA repeats have been associated with Gilbert syndrome which is a mild and often asymptomatic hyperbilirubinemia (PMID: 8596320, 11003624). Furthermore, individuals who are homozygous for this variant present with elevated total bilirubin levels that are consistent with Gilbert syndrome (PMID: 7565971, 9435989, 16610035, 28520360, 11003624, 26467199). When this variant is found in compound heterozygosity with a pathogenic UGT1A1 coding variant, it may lead to a more pronounced enzyme deficiency, higher total bilirubin levels, and a clinical presentation overlapping Crigler-Najjar syndrome (PMID: 9639672, 11370628). Functional studies have shown that this variant reduces UGT1A1 gene expression (PMID: 9639672). The c.-53_-52insTA variant is present in the gnomAD population database at a frequency of 23% (7043/30582) in the heterozygous state and a frequency of 5.8% (1778/30582) in the homozygous state. Based on the available evidence, the c.-53_-52insTA variant is classified as Pathogenic.
Difficult and Complicated Liver Diseases and Artificial Liver Center, Beijing You An Hospital, Capital Medical University	RCV000999559	SCV001156252	pathogenic	Gilbert syndrome	2019-05-01	no assertion criteria provided	case-control